injection, suspension in the vial
Human papillomavirus vaccine [Type 16, 18] ( Recombinant , with adjuvant , adsorbed).<\/p>\n\n\n\n
Cervarix is a vaccine intended to protect against diseases caused by infection with human papillomavirus (HPV) by the age of 9.
<\/p>\n\n\n\n
These diseases include:<\/p>\n\n\n\n
The types of human papillomavirus (HPV) included in the vaccine (HPV types 16 and 18) cause approximately 70% of cases of cervical cancer, 90% of cases of cancer of the rectal opening, 70% of HPV-related cell changes that are precursors to cancer in external parts of the genitals and vagina and 78% of HPV-related cell changes that are precursors to cancer of the rectal opening. Other types of HPV can also cause genital and rectal cancer. Cervarix does not protect against all types of human papillomavirus.
<\/p>\n\n\n\n
When a woman or man is vaccinated with Cervarix, the body’s immune system produces antibodies to HPV 16 and 18.
<\/p>\n\n\n\n
Cervarix is \u200b\u200bnot contagious and therefore cannot cause HPV-related diseases.
<\/p>\n\n\n\n
Cervarix is \u200b\u200bnot used to treat HPV-related diseases that already exist at the time of vaccination.
<\/p>\n\n\n\n
Cervarix should be used in accordance with official guidelines.
<\/p>\n\n\n\n
Talk to your doctor or pharmacist before taking Cervarix<\/p>\n\n\n\n
Fainting can occur (mainly in adolescents) after, or even before, any needle injection. Therefore, tell your doctor or nurse if you or your child have fainted from a previous injection .
<\/p>\n\n\n\n
As with all vaccines, Cervarix may not provide complete protection to everyone who is vaccinated.
<\/p>\n\n\n\n
Cervarix does not provide protection against disease caused by HPV 16 or 18 infection in those who have already been infected with HPV 16 or 18 at the time of vaccination.
<\/p>\n\n\n\n
Vaccination can protect against cervical cancer, but does not replace routine Pap smears. You should continue to follow your doctor’s instructions for regular cell sample checks ( screening for cell changes in the cervix caused by HPV) as well as preventive and protective measures.
<\/p>\n\n\n\n
Cervarix does not protect against all types of human papillomavirus. Preventive measures against exposure to HPV and sexually transmitted diseases should therefore continue to be taken.
<\/p>\n\n\n\n
Cervarix does not protect against diseases not caused by human papillomavirus.<\/p>\n\n\n\n
Cervarix can be given concomitantly with a combined booster vaccine containing diphtheria (d), tetanus (T) and pertussis [acellular] (pa) with \/ without polio [inactivated] (IPV) (dTpa, dTpa-IPV vaccine), with a combined hepatitis A and hepatitisB vaccine (Twinrix) or a hepatitis B vaccine (Engerix-B) or with a tetanus-conjugated meningococcal group A, C, W-135, Y vaccine (MenACWY-TT). When the vaccines are given at the same visit, however, different injection sites (other body part, eg opposite arm) must be used.
<\/p>\n\n\n\n
Cervarix may not have an optimal effect if used in combination with medicines that inhibit the immune system.
<\/p>\n\n\n\n
In clinical trials , oral contraceptives (eg birth control pills ) did not reduce the protection given by Cervarix.
<\/p>\n\n\n\n
Tell your doctor if you are taking, have recently taken or might take any other medicines or have recently received any other vaccine.<\/p>\n\n\n\n
If you are pregnant, if you become pregnant during the vaccination series or if you are trying to become pregnant, it is recommended that you postpone or interrupt the vaccination until after the end of the pregnancy.
<\/p>\n\n\n\n
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this vaccine.<\/p>\n\n\n\n
Cervarix is \u200b\u200bunlikely to affect your ability to drive or use machines. But do not drive or use machines if you feel unwell.<\/p>\n\n\n\n
This medicine contains less than 1 mmol sodium (23 mg) per dose , ie essentially ‘sodium-free’.
<\/p>\n\n\n\n
How the vaccine should be given<\/strong><\/p>\n\n\n\n Your doctor or nurse will give you Cervarix as an injection into the upper arm muscle. How much should be given<\/strong><\/p>\n\n\n\n Cervarix is \u200b\u200bintended for use from the age of 9 years. The total number of injections you will be given depends on your age at the time of the first injection: If you are 9-14 years old<\/em><\/strong> You will receive 2 injections: First injection: on the selected date<\/p>\n\n\n\n Second injection: given between 5 and 13 months after the first injection, a If you are 15 years or older<\/em><\/strong> You will receive 3 injections: First injection: on the selected date<\/p>\n\n\n\n Second injection: 1 month after the first injection, a<\/p>\n\n\n\n Third injection: 6 months after first injection a The dosing schedule may be changed if necessary. Talk to your doctor for more information. If the first dose is given with Cervarix, it is recommended that you continue the entire vaccination series with Cervarix (and no other HPV vaccine). Cervarix is \u200b\u200bnot recommended for use under 9 years of age. The vaccine should not be given into a vein.<\/p>\n\n\n\n It is important that you follow the instructions from the doctor \/ nurse regarding return visits for future doses . Consult your doctor if you forget to come on time. If you do not complete the vaccination series (two or three injections depending on your age at the time of vaccination), you risk not getting the best response and protection from your vaccination. Like all medicines, this vaccine can cause side effects , although not everybody gets them. The following adverse reactions have been reported in clinical trials: Side effects reported after Cervarix approval:<\/p>\n\n\n\n These reactions normally occur before leaving the care facility. If your child gets any of these symptoms, contact a doctor immediately.<\/p>\n\n\n\n Reporting of side effects<\/em><\/p>\n\n\n\n If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Medical Products Agency, www.lakemedelsverket.se. By reporting side effects, you can help increase drug safety information. <\/p>\n\n\n\n Keep this vaccine out of the reach and sight of children. Do not use this medicine after the expiry date which is stated on the carton. The expiration date is the last day of the specified month. Store in a refrigerator (2 \u00b0 C – 8 \u00b0 C).<\/p>\n\n\n\n Do not freeze.<\/p>\n\n\n\n Store in the original package. Sensitive to light. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.<\/p>\n\n\n\n <\/p>\n\n\n\n Injection, suspension. Cervarix is \u200b\u200ba milky, white suspension. Cervarix single-dose bottles (0.5 ml) are supplied in packs of 1, 10 and 100 pieces. Not all pack sizes may be marketed.<\/p>\n\n\n\n GlaxoSmithKline Biologicals SA<\/p>\n\n\n\n Rue de l’Institut 89<\/p>\n\n\n\n B-1330 Rixensart, Belgium Contact the representative of the marketing authorization holder to find out more about this medicine: Cervarix is a vaccine intended to protect against diseases caused by infection with human papillomavirus (HPV) by the age of 9.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2203,2200],"tags":[7467,7473,7472,7470,7471,2212,7469,7468],"class_list":["post-6664","post","type-post","status-publish","format-standard","hentry","category-c","category-medicines","tag-cervarix","tag-cervarix-dosage","tag-cervarix-dose","tag-cervarix-side-effects","tag-cervarix-uses","tag-medicine","tag-what-cervarix-is-used-for","tag-what-is-cervarix"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/6664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=6664"}],"version-history":[{"count":3,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/6664\/revisions"}],"predecessor-version":[{"id":11523,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/6664\/revisions\/11523"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=6664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=6664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=6664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\nIf you miss a dose<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n4. Possible side effects<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n5. How to store Cervarix<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n6. Contents of the packaging and other information<\/h2>\n\n\n\n
Content declaration<\/h2>\n\n\n\n
–<\/td> The active substance is:
Human papillomavirus 1<\/sup> type 16 L1 protein 2, 3, 4<\/sup>Human papillomavirus 1<\/sup> type 18 L1 protein 2, 3, 4<\/sup><\/td>
20 micrograms20 micrograms<\/td><\/tr> <\/td> 1<\/sup> Human papillomavirus = HPV<\/td>
<\/td><\/tr> <\/td> 2 <\/sup>adjuvants AS04 containing:3-O-desacyl-4′-monophosphoryl lipid A (MPL) 3<\/sup><\/td>
50 micrograms<\/td><\/tr> <\/td> 3 <\/sup>adsorbed on aluminum hydroxide, hydrated (Al (OH) 3<\/sub> ) 0.5 milligrams Al 3+<\/sup> (total)
4<\/sup> L1 protein in the form of non-infectious virus-like particles produced by recombinant DNA technology in an expression system consisting of baculovirus with Hi-5 Rix4446 cells from the insect Trichoplusia ni<\/em><\/td><\/tr>–<\/td> The other ingredients are sodium chloride (NaCl), sodium dihydrogen phosphate dihydrate (NaH 2<\/sub> PO 4<\/sub> \u00b7 2 H 2<\/sub> O) and water for injections.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n What the medicine looks like and the contents of the pack<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\nMarketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\nBelgique \/ <\/strong>Belgi\u00eb \/ <\/strong>Belgien<\/strong>GlaxoSmithKline Pharmaceuticals sa \/ nvTel: + 32 10 85 52 00<\/td> Lithuania<\/strong>GlaxoSmithKline Lithuania UABTel: +370 5 264 90 00info.lt@gsk.com<\/td><\/tr> Bulgaria<\/strong>The GlaxoSmithKlein \u0415\u041e\u041e\u0414Tel. + 359 2 953 10 34<\/td> Luxembourg \/ Luxemburg<\/strong>GlaxoSmithKline Pharmaceuticals sa \/ nvTel: + 32 10 85 52 00<\/td><\/tr> Czech Republic<\/strong>GlaxoSmithKline sroTel: + 420 2 22 00 11 11cz.info@gsk.com<\/td> Hungary<\/strong>GlaxoSmithKline Kft.Tel .: + 36-1-2255300<\/td><\/tr> Denmark<\/strong>GlaxoSmithKline Pharma A \/ STel: + 45 36 35 91 00dk-info@gsk.com<\/td> Malta<\/strong>GlaxoSmithKline (Malta) LtdTel: + 356 21 238131<\/td><\/tr> Germany<\/strong>GlaxoSmithKline GmbH & Co. KGTel: + 49 (0) 89 360448701produkt.info@gsk.com<\/td> The Netherlands<\/strong>GlaxoSmithKline BVTel: + 31 (0) 30 69 38 100nlinfo@gsk.com<\/td><\/tr> Eesti<\/strong>GlaxoSmithKline Eesti O\u00dcTel: +372 667 6900estonia@gsk.com<\/td> Norway<\/strong>GlaxoSmithKline ASTel: + 47 22 70 20 00<\/td><\/tr> Greece<\/strong>GlaxoSmithKline AEBET\u03b7\u03bb: + 30 210 68 82 100<\/td> Austria<\/strong>GlaxoSmithKline Pharma GmbH.Tel: + 43 (0) 1 970 750at.info@gsk.com<\/td><\/tr> Spain<\/strong>GlaxoSmithKline, SATel: + 34 902 202 700es-ci@gsk.com<\/td> Poland<\/strong>GSK Services Sp. z ooTel .: + 48 (22) 576 9000<\/td><\/tr> France<\/strong>GlaxoSmithKline LaboratoryTel: + 33 (0) 1 39 17 84 44diam@gsk.com<\/td> Portugal<\/strong>GlaxoSmithKline – Pharmaceutical Products, Lda.Tel: + 351 21 412 95 00FI.PT@gsk.com<\/td><\/tr> Croatia<\/strong>GlaxoSmithKline dooTel .: + 385 (0) 1 6051999<\/td> Romania<\/strong>GlaxoSmithKline (GSK) SRLTel: +40 (0) 21 3028 208<\/td><\/tr> Ireland<\/strong>GlaxoSmithKline (Ireland) LtdTel: + 353 (0) 1 495 5000<\/td> Slovenia<\/strong>GlaxoSmithKline dooTel: + 386 (0) 1 280 25 00medical.x.si@gsk.com<\/td><\/tr> Iceland<\/strong>Vistor hf.Phone: +354 535 7000<\/td> Slovak Republic<\/strong>GlaxoSmithKline Slovakia sroTel: + 421 (0) 2 48 26 11 11recepcia.sk@gsk.com<\/td><\/tr> Italy<\/strong>GlaxoSmithKline SpATel: + 39 (0) 45 9218111<\/td> Finland \/ Finland<\/strong>GlaxoSmithKline OyPuh \/ Tel: + 358 10 30 30 30finland.tuoteinfo@gsk.com<\/td><\/tr> \u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/strong>GlaxoSmithKline (Cyprus) Ltd:\u0397\u03bb: + 357 22 39 70 00gskcyprus@gsk.com<\/td> <\/td><\/tr> Latvia<\/strong>GlaxoSmithKline Latvia SIATel: + 371 67312687lv-epasts@gsk.com<\/td> United Kingdom<\/strong>GlaxoSmithKline UKTel: + 44 (0) 800 221 441customercontactuk@gsk.com<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"